Status:

RECRUITING

Hypofractionated Vs Conventional Fractionated Radiotherapy After Breast Conserving Surgery

Lead Sponsor:

Fudan University

Conditions:

Breast Cancer

Eligibility:

FEMALE

18-70 years

Phase:

NA

Brief Summary

The study was designed to investigate whether hypofractionated radiotherapy(HF-RT) is noninferior to conventionally fractionated radiotherapy (CF-RT) in terms of tumor loco-regional control for patien...

Detailed Description

Eligible patients after breast conserving surgery will be randomized 1:1 into hypofractionated radiotherapy (HF-RT) group or conventionally fractionated radiotherapy (CF-RT) group. Patients in HF-RT ...

Eligibility Criteria

Inclusion

  • Female
  • Age18-70 years
  • Imaging examination confirmed single lesion. if the tumor is multiple, it needs to be removed by single quadrantectomy
  • Receive breast conserving surgery with negative margins
  • Axillary lymph nodes treatment: Sentinel lymph node biopsy or level I/II axillary lymph node dissection. If the sentinel lymph node is negative, the axillary lymph node dissection can be omitted. If it is positive, level I/II axillary lymph node dissection with or more than 10 lymph nodes is needed.
  • The tumor bed is labeled with clips and it can be drawn on the treatment planning system.
  • Pathologically confirmed invasive breast cancer
  • Pathologically stage is T1-3N0-3M0
  • Immunohistochemical examination is conducted to determine the status of ER, PR, HER2, Ki67 after surgery
  • No distant metastases
  • No supraclavicular or internal mammary nodes metastases
  • No neoadjuvant chemotherapy
  • Fit for postoperative radiotherapy. No contraindications to radiotherapy
  • KPS≥80
  • Signed informed consent

Exclusion

  • T4 or M1 breast cancer
  • Supraclavicular or internal mammary nodes metastases
  • Pathologically confirmed DCIS only without an invasive component
  • Bilateral breast cancer or historically confirmed contralateral invasive breast cancer
  • Treated with neoadjuvant chemotherapy or neoadjuvant endocrine therapy
  • Multiple lesions can not be removed by single quadrantectomy
  • Suspicious unresected and microcalcification, densities, or palpable abnormalities (in the ipsilateral or contralateral breast)
  • KPS ≤ 70
  • Patients with severe non-malignant comorbidity in cardiovascular or respiration system
  • Concurrent or previous malignancy excluding basal or squamous cell carcinoma of the skin
  • Previous radiotherapy to the chest wall or regional lymph node areas
  • Patients with medical contraindication for radiotherapy: systemic lupus erythematosus, cirrhosis
  • Pregnant or lactating
  • Conditions indicating that the patient cannot go through the radiation therapy or follow up
  • Unable or unwilling to sign informed consent

Key Trial Info

Start Date :

July 1 2018

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 30 2028

Estimated Enrollment :

4052 Patients enrolled

Trial Details

Trial ID

NCT04025164

Start Date

July 1 2018

End Date

June 30 2028

Last Update

July 18 2019

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Guizhou Provincial People's Hospital

Guiyang, Guizhou, China, 550002

2

Suzhou Municipal hospital

Suzhou, Jiangsu, China, 215000

3

The Second Hospital of Dalian Medical University

Dalian, Liaoning, China, 116044

4

Shanghai Huangpu District Central Hospital

Shanghai, Shanghai Municipality, China, 200002

Hypofractionated Vs Conventional Fractionated Radiotherapy After Breast Conserving Surgery | DecenTrialz